We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+24.48%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.93%
AUM
$72.6B
AUM Growth
+$8.69B
(+14%)
Cap. Flow
+$958M
Cap. Flow % of AUM
Cap. Flow %
1.32%
Top 10 Holdings %
Top 10 Hldgs %
12.01%
Holding
3,761
New
548
Increased
1,084
Reduced
1,502
Closed
621
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 2 |
NVIDIA
NVDA
|
+$938M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$639M |
| 4 |
Netflix
NFLX
|
+$598M |
| 5 |
Amazon
AMZN
|
+$575M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.46B |
| 2 |
Sandisk
SNDK
|
+$1.13B |
| 3 |
Apple
AAPL
|
+$426M |
| 4 |
Linde
LIN
|
+$316M |
| 5 |
Vertiv
VRT
|
+$297M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.58% |
| 2 | Healthcare | 14.83% |
| 3 | Consumer Discretionary | 11.24% |
| 4 | Industrials | 10.49% |
| 5 | Communication Services | 8.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2701
Instil Bio
TIL
$39.1M
| $387K | ﹤0.01% |
50,300
-8,800
| -15% | -$71K |
2025 Q4
2 quarters
|
|
2702
GigaCloud Technology
GCT
$2.16B
| $386K | ﹤0.01% |
12,200
-66,609
| -85% | -$2.63M |
2026 Q1
1 quarter
|
|
2703
Blink Charging
BLNK
$61.2M
| $382K | ﹤0.01% |
597,584
-904,016
| -60% | -$655K |
2025 Q3
3 quarters
|
|
2704
Catalyst Bancorp
CLST
$68.3M
| $381K | ﹤0.01% |
23,100
-100
| -0.4% | -$1.61K |
2024 Q3
7 quarters
|
|
2705
Bolt Biotherapeutics
BOLT
$7.98M
| $380K | ﹤0.01% |
98,625
+21,400
| +28% | +$100K |
2021 Q2
20 quarters
|
|
2706
Capital Group International Focus Equity ETF
CGXU
$6.55B
| $377K | ﹤0.01% |
10,900
+3,900
| +56% | +$130K |
2025 Q4
2 quarters
|
|
2707
IZEA Worldwide
IZEA
$40.4M
| $375K | ﹤0.01% |
101,240
-46,500
| -31% | -$181K |
2021 Q2
20 quarters
|
|
2708
FinWise Bancorp
FINW
$145M
| $374K | ﹤0.01% |
25,800
-2,226
| -8% | -$33.1K |
2022 Q1
17 quarters
|
|
2709
Newmark Group
NMRK
$2.08B
| $374K | ﹤0.01% |
24,745
-337,800
| -93% | -$5.16M |
2026 Q1
1 quarter
|
|
2710
Invesco S&P 500 High Beta ETF
SPHB
$907M
| $373K | ﹤0.01% |
+2,400
| New | +$335K |
2026 Q2
0 quarters
|
|
2711
Codere Online
CDRO
$427M
| $373K | ﹤0.01% |
+39,000
| New | +$360K |
2026 Q2
0 quarters
|
|
2712
Actinium Pharmaceuticals
ATNM
$43.4M
| $373K | ﹤0.01% |
380,491
-91,109
| -19% | -$105K |
2024 Q2
8 quarters
|
|
2713
Rapid Micro Biosystems
RPID
$40.9M
| $367K | ﹤0.01% |
212,101
+85,484
| +68% | +$180K |
2023 Q1
13 quarters
|
|
2714
Marker Therapeutics
MRKR
$18.8M
| $367K | ﹤0.01% |
249,423
+74,129
| +42% | +$108K |
2021 Q2
20 quarters
|
|
2715
High Templar Tech Ltd
HTT
$314M
| $367K | ﹤0.01% |
143,213
+120,013
| +517% | +$313K |
2026 Q1
1 quarter
|
|
2716
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$53.4M
| $366K | ﹤0.01% |
+47,500
| New | +$639K |
2026 Q2
0 quarters
|
|
2717
Mativ Holdings
MATV
$648M
| $366K | ﹤0.01% |
48,300
-29,800
| -38% | -$257K |
2025 Q3
3 quarters
|
|
2718
Under Armour Class C
UA
$1.96B
| $363K | ﹤0.01% |
+58,400
| New | +$336K |
2026 Q2
0 quarters
|
|
2719
iShares Russell 2000 Value ETF
IWN
$13.7B
| $362K | ﹤0.01% |
+1,636
| New | +$342K |
2026 Q2
0 quarters
|
|
2720
Key Tronic
KTCC
$23.9M
| $359K | ﹤0.01% |
86,900
-2,500
| -3% | -$8.19K |
2020 Q4
22 quarters
|
|
2721
Dentsply Sirona
XRAY
$1.81B
| $355K | ﹤0.01% |
33,458
-1,535,900
| -98% | -$16.8M |
2023 Q3
11 quarters
|
|
2722
iBio
IBIO
$54M
| $355K | ﹤0.01% |
+202,847
| New | +$363K |
2026 Q2
0 quarters
|
|
2723
Assured Guaranty
AGO
$3.05B
| $353K | ﹤0.01% |
4,400
+1,900
| +76% | +$150K |
2026 Q1
1 quarter
|
|
2724
Arts-Way Manufacturing Co
ARTW
$16.1M
| $353K | ﹤0.01% |
134,074
-7,400
| -5% | -$19.3K |
2017 Q1
37 quarters
|
|
2725
Silvia, Inc. Common Stock
SVIA
$334M
| $352K | ﹤0.01% |
+228,800
| New | +$420K |
2026 Q2
0 quarters
|
|
Similar funds
Jim Simons's Q2 2026 Portfolio in Review
As of Q2 2026, Jim Simons held 3,761 positions worth $72.6B, up 14% from $63.9B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2026 filing shows 548 new, 1,084 increased, 1,502 reduced and 621 closed positions. Its largest new stake was Amazon: 2,290,710 shares worth $546M. The largest sale was Micron Technology, an estimated $1.46B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2026 buy was Amazon: 2,290,710 shares worth $546M.
- Jim Simons added most to Meta Platforms (Facebook) in Q2 2026, an estimated $1.08B increase.
- Jim Simons's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.46B.
- Jim Simons fully exited Applovin in Q2 2026, selling an estimated $174M.
- Jim Simons's ten largest holdings make up 12% of its $72.6B portfolio in Q2 2026.
- Jim Simons opened 548 new positions and closed 621 in Q2 2026.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $72.6B.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.